drugset
drugset / Trial / NCT00094159

Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors

NCT00094159 ↗

Phase 1 Completed Sunesis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether SNS-595 given intravenously weekly for 3 weeks is safe.

Timeline

Start
2004-10
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Vosaroxin Small molecule — Intravenous

Indications

neoplasm